Clinical trial
Cardiac Valve Complications in Prolactinomas Treated With Cabergoline
NCT00460616 · Federico II University, Other · Completed
Key facts
| NCT number | NCT00460616 |
|---|---|
| Title | Cardiac Valve Complications in Prolactinomas Treated With Cabergoline |
| Official title | Observational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With Cabergoline |
| Acronym | ValveCab |
| Lead sponsor | Federico II University, Other |
| Status | Completed |
| Study type | Observational |
| Conditions | Prolactinomas |
| Intervention type | Drug |
| Interventions | Cabergoline |
| Enrollment | 50 |
| Start date | Jan 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Apr 16, 2007 |
| Last update posted | Apr 16, 2008 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: